Scott Morton, Fiona and Seabright, Paul (2013) Research into biomarkers: how does drug procurement affect the design of clinical trials? Health Management, Policy and Innovation, vol. 1 (n° 3). pp. 1-15.

[thumbnail of medias/stories/IAST/research into biomarkets.pdf]
Preview
Text
Download (227kB) | Preview

Abstract

This paper examines incentives for pharmaceutical firms to invest in biomarkers that predict which groups of sufferers from a certain medical condition will respond well to a particular treatment. We show that when pricing of the treatment is imperfectly responsive to effectiveness, firms undertaking clinical trial have an incentive to expand the relevant treatment population in border both to increase the probability of a statistically significant result, and to increase future revenues. Firms may fail to include potentially promising biomarkers in clinical trials, may include such biomarkers without disclosing them in the public protocol, and may fail to disclose the relevance of clinically predictive biomarkers. We show how many existing pricing and procurement schemes create adverse incentives of this kind, and discuss various mechanisms that may help to mitigate such effects.

Item Type: Article
Language: English
Date: June 2013
Refereed: Yes
Uncontrolled Keywords: clinical trials, biomarkers, pharmaceuticals, medical procurement
Subjects: B- ECONOMIE ET FINANCE
Divisions: TSE-R (Toulouse)
Site: UT1
Date Deposited: 09 Jul 2014 17:37
Last Modified: 22 Nov 2023 10:35
OAI Identifier: oai:tse-fr.eu:27417
URI: https://publications.ut-capitole.fr/id/eprint/15685
View Item

Downloads

Downloads per month over past year